Responses
Clinical and epidemiological research
Extended report
Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease
Compose a Response to This Article
Other responses
No responses have been published for this article.